Newsroom | Gilead - Gilead Sciences
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies. September 05, 2024. Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer. August 14, 2024. Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA. 1. 2. 3. 4. 5.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023. “This was another strong year of revenue growth for Gilead’s base business, driven by both HIV and Oncology,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.
Gilead Provides Update on U.S. Indication for Trodelvy® in …
1 day ago · Back. Foster City, Calif., October 18, 2024 – Gilead Sciences, Inc. today announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy® (sacituzumab govitecan-hziy; SG) for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing ...
Gilead Presents Additional Efficacy, Safety and Demographic Data …
Oct 7, 2024 · FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the ...
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated ...
22 hours ago · On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally ...
Gilead Sciences Announces Third Quarter 2022 Financial Results
Oct 27, 2022 · Gilead Sciences Announces Third Quarter 2022 Financial Results. October 27, 2022. Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion. Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion. Oncology Sales Increased 79% Year-Over-Year to $578 million.
Gilead Sciences, Inc. (GILD) Latest Stock News & Headlines
Get the latest Gilead Sciences, Inc. (GILD) stock news and headlines to help you in your trading and investing decisions.
Gilead withdraws bladder cancer drug in US after failed trial
1 day ago · Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...
Gilead withdraws Trodelvy in bladder cancer after trial flop
1 day ago · Following the setback in that study, called EVOKE-01, Gilead recognized an impairment charge of $2.4 billion. Trodelvy was the crown jewel in Gilead’s $21 billion acquisition of Immunomedics in ...
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in …
1 day ago · Gilead reported worldwide Trodelvy sales of $628 million for the first six months of the year, representing less than 5% of the company's revenue of more than $13.6 billion for the period.